Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors.

× No keyword cloud information.

14 in total

1. Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data.

Authors: Gordon Graham; Suneel Gupta; Leon Aarons
Journal: J Pharmacokinet Pharmacodyn Date: 2002-02 Impact factor: 2.745

2. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.

Authors: Cornelia B Landersdorfer; Yan-Ling He; William J Jusko
Journal: Br J Clin Pharmacol Date: 2012-03 Impact factor: 4.335

3. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.

Authors: Cornelia B Landersdorfer; Yan-Ling He; William J Jusko
Journal: Br J Clin Pharmacol Date: 2012-03 Impact factor: 4.335

4. Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.

Authors: Yusuke Tadayasu; Akiko Sarashina; Yasuhiro Tsuda; Shinji Tatami; Christian Friedrich; Silke Retlich; Alexander Staab; Mikihisa Takano
Journal: J Pharm Pharm Sci Date: 2013 Impact factor: 2.327

5. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.

Authors: E Näslund; J Bogefors; S Skogar; P Grybäck; H Jacobsson; J J Holst; P M Hellström
Journal: Am J Physiol Date: 1999-09

Review 6. Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors: Cornelia B Landersdorfer; William J Jusko
Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447

Review 7. Biology of incretins: GLP-1 and GIP.

Authors: Laurie L Baggio; Daniel J Drucker
Journal: Gastroenterology Date: 2007-05 Impact factor: 22.682

8. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.

Authors: Leo Thomas; Matthias Eckhardt; Elke Langkopf; Moh Tadayyon; Frank Himmelsbach; Michael Mark
Journal: J Pharmacol Exp Ther Date: 2008-01-25 Impact factor: 4.030

9. Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation.

Authors: Nieves Vélez de Mendizábal; Robert M Strother; Sherif S Farag; Hal E Broxmeyer; Steven Messina-Graham; Shripad D Chitnis; Robert R Bies
Journal: Clin Pharmacokinet Date: 2014-03 Impact factor: 6.447

10. Pharmacokinetic-pharmacodynamic modelling of biomarker response to sitagliptin in healthy volunteers.

Authors: Bo-Hyung Kim; Sung Eun Kim; Dongwoo Kang; Kyoung Soo Lim; Jung-Ryul Kim; In-Jin Jang; Sang-Goo Shin; Seo Hyun Yoon; Joo-Youn Cho; Kyung-Sang Yu
Journal: Basic Clin Pharmacol Toxicol Date: 2013-05-20 Impact factor: 4.080